Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients
- 193 Downloads
This study was performed to examine possible use of thymidine kinase 1 concentration in serum (STK1) for prognosis of non-Hodgkin’s lymphoma patients following chemotherapy treatment.
The STK1 levels of 37 patients were determined by enhanced chemiluminescent dot-blot assay on the day before chemotherapy, and on day 1 and day 28 after start of the treatment. The specificity and sensitivity was evaluated by Western blot with anti-TK1 IgY antibody and by receiver operating characteristic (ROC) analysis.
Western blot and ROC analysis of TK1 in serum showed high specificity and sensitivity. The mean STK1 level of the non-Hodgkin’s lymphoma patients was significantly higher compared to healthy persons (p < 0.001). The mean STK1 level increased significantly (p < 0.001) on day 1 and then declined, reaching on day 28 values corresponding to those of healthy persons. The mean STK1 values before treatment and at 1 and 28 days after start of the treatment also correlated significantly with the clinical response (CR, PR and NR) and five-year survival.
Although the number of patients was limited in this study, TK1 in serum might possess an important reference value in the evaluation of treatment and prognosis of non-Hodgkin’s lymphoma following chemotherapy.
KeywordsThymidine kinase 1 Non-Hodgkin’s lymphoma Chemotherapy Enhanced chemiluminescent (ECL) dot-blot assay
This investigation was supported by Sino-Swed Tongkang Bio-Tech Ltd., Shenzhen, China, and by Departments No. 85 and No. 411 at PLA Hospital, Shanghai, China.
Conflict of interest statement
Zhu-Lin Pan, Xing-Ying Ji and Yan-Min Shi report no conflict of interest. Ji Zhou is CEO of SSTK Ltd, and Ellen He and Sven Skog are scientific consulters to SSTK Ltd., the company that produces the TK1 kit. The authors alone are responsible for the content and writing of the paper.
- HengZhi C, Zhou H, Tian NB, He E, Skog S (2008) Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumors. Anticancer Res 28:3897–3908Google Scholar
- Törnevik Y, Ullman BJ, Balzarini J et al (1995) Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human Immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine 5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49:829–837CrossRefPubMedGoogle Scholar
- Xu XH, Zhang YM, Shu XH et al (2008) Serological thymidine kinase 1 reflects progression of pre-malignant and malignant tumours during therapy. Mol Med Rep 1:705–711Google Scholar
- Zhang ZN, Shen D (1998) Diagnosis of blood disease and response criteria. The second version. Beijing Science Press, Beijing, pp 168–349Google Scholar
- Zou L, Zhang PG, Zou S, Li Y, He Q (2002) The half-life of cytosolic thymidine kinase in serum by ECL dot bolt: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Marker 17:135–140Google Scholar